Cardiogenic shock risk factors: Difference between revisions

Jump to navigation Jump to search
Line 21: Line 21:
*Sinus tachycardia > 110 bpm
*Sinus tachycardia > 110 bpm
*Heart rate < 60 bpm<ref>{{Cite journal  | last1 = Antman | first1 = EM. | last2 = Hand | first2 = M. | last3 = Armstrong | first3 = PW. | last4 = Bates | first4 = ER. | last5 = Green | first5 = LA. | last6 = Halasyamani | first6 = LK. | last7 = Hochman | first7 = JS. | last8 = Krumholz | first8 = HM. | last9 = Lamas | first9 = GA. | title = 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal = J Am Coll Cardiol | volume = 51 | issue = 2 | pages = 210-47 | month = Jan | year = 2008 | doi = 10.1016/j.jacc.2007.10.001 | PMID = 18191746 }}</ref>
*Heart rate < 60 bpm<ref>{{Cite journal  | last1 = Antman | first1 = EM. | last2 = Hand | first2 = M. | last3 = Armstrong | first3 = PW. | last4 = Bates | first4 = ER. | last5 = Green | first5 = LA. | last6 = Halasyamani | first6 = LK. | last7 = Hochman | first7 = JS. | last8 = Krumholz | first8 = HM. | last9 = Lamas | first9 = GA. | title = 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal = J Am Coll Cardiol | volume = 51 | issue = 2 | pages = 210-47 | month = Jan | year = 2008 | doi = 10.1016/j.jacc.2007.10.001 | PMID = 18191746 }}</ref>
*[[ST]] elevation<ref name="pmid9459474">{{cite journal| author=Hathaway WR, Peterson ED, Wagner GS, Granger CB, Zabel KM, Pieper KS et al.| title=Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. | journal=JAMA | year= 1998 | volume= 279 | issue= 5 | pages= 387-91 | pmid=9459474 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9459474  }} </ref>
*[[ST]] depression<ref name="pmid9459474">{{cite journal| author=Hathaway WR, Peterson ED, Wagner GS, Granger CB, Zabel KM, Pieper KS et al.| title=Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. | journal=JAMA | year= 1998 | volume= 279 | issue= 5 | pages= 387-91 | pmid=9459474 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9459474  }} </ref>
*Q waves (EKG evidence of prior myocardial infarction)<ref name="pmid9459474">{{cite journal| author=Hathaway WR, Peterson ED, Wagner GS, Granger CB, Zabel KM, Pieper KS et al.| title=Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. | journal=JAMA | year= 1998 | volume= 279 | issue= 5 | pages= 387-91 | pmid=9459474 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9459474  }} </ref>
*According to the analysis of PURSUIT trial database<ref name="pmid10987585">{{cite journal| author=Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW et al.| title=Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 3 | pages= 685-92 | pmid=10987585 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10987585  }} </ref> in [[non-ST-segment elevation myocardial infarction|Non-ST-segment elevation myocardial infarction]] [[patients]] who received [[eptifibatide]] saw their 30-day mortality risk reduced by 50%. In this trial, risk factors for development of cardiogenic shock like age and presence of [[ST]] depression in the initial [[EKG]], in [[patients]] with [[non-ST-segment elevation myocardial infarction|Non-ST-segment elevation myocardial infarction]] was also noted.
*According to the analysis of PURSUIT trial database<ref name="pmid10987585">{{cite journal| author=Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW et al.| title=Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 3 | pages= 685-92 | pmid=10987585 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10987585  }} </ref> in [[non-ST-segment elevation myocardial infarction|Non-ST-segment elevation myocardial infarction]] [[patients]] who received [[eptifibatide]] saw their 30-day mortality risk reduced by 50%. In this trial, risk factors for development of cardiogenic shock like age and presence of [[ST]] depression in the initial [[EKG]], in [[patients]] with [[non-ST-segment elevation myocardial infarction|Non-ST-segment elevation myocardial infarction]] was also noted.
*


==References==
==References==

Revision as of 23:41, 30 April 2014

Cardiogenic Shock Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiogenic shock from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiogenic shock risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiogenic shock risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiogenic shock risk factors

CDC on Cardiogenic shock risk factors

Cardiogenic shock risk factors in the news

Blogs on Cardiogenic shock risk factors

Directions to Hospitals Treating Cardiogenic shock

Risk calculators and risk factors for Cardiogenic shock risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

The identification of high-risk groups for developing cardiogenic shock, particularly in ACS patients (since this is the most common cause of this type of shock), and its promoting factors is mandatory for the improvement of the survival rate of these patients by providing adequate therapeutic measures and avoiding others which might otherwise lead to iatrogenic shock.[1]

Risk Factors

According to several studies there are risk factors which are associated with the development of cardiogenic shock. These include:

References

  1. Hasdai, David. (2002). Cardiogenic shock : diagnosis and treatmen. Totowa, N.J.: Humana Press. ISBN 1-58829-025-5.
  2. 2.0 2.1 2.2 2.3 Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S (1993). "Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group". Am J Med. 94 (3): 265–73. PMID 8452150.
  3. 3.0 3.1 3.2 3.3 Hands, Mark E.; Rutherford, John D.; Muller, James E.; Davies, Glenn; Stone, Peter H.; Parker, Corette; Braunwald, Eugene (1989). "The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors". Journal of the American College of Cardiology. 14 (1): 40–46. doi:10.1016/0735-1097(89)90051-X. ISSN 0735-1097.
  4. Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M; et al. (2000). "Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction". J Am Coll Cardiol. 35 (1): 136–43. PMID 10636271.
  5. Antman, EM.; Hand, M.; Armstrong, PW.; Bates, ER.; Green, LA.; Halasyamani, LK.; Hochman, JS.; Krumholz, HM.; Lamas, GA. (2008). "2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 51 (2): 210–47. doi:10.1016/j.jacc.2007.10.001. PMID 18191746. Unknown parameter |month= ignored (help)
  6. 6.0 6.1 6.2 Hathaway WR, Peterson ED, Wagner GS, Granger CB, Zabel KM, Pieper KS; et al. (1998). "Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries". JAMA. 279 (5): 387–91. PMID 9459474.
  7. Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW; et al. (2000). "Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation". J Am Coll Cardiol. 36 (3): 685–92. PMID 10987585.